- Ideas
- Markets
- Cryptocurrencies
- Crypto Screener
- Prices
- Market Cap charts
- Bitcoin
- XRP
- Ethereum
- Bitcoin Cash
- EOS
- Stellar
- Litecoin
- Bitcoin SV
- Tether
Crypto Market Cap, BTC/USD, ETH/USD, USDT/USD, XRP/USD, Bitcoin
- Currencies
- Stocks
- Earnings Calendar
- Stock Screener
- Large-cap
- Top gainers
- Top losers
- Most active
- Most volatile
- Overbought
- Oversold
- All-time high
- All-time low
- High-dividend
- Sector & Industry
Apple, Advanced Micro Devices Inc, Amazon Com Inc, TESLA INC, NETFLIX INC, Facebook Inc
- Indices
S&P 500, Nasdaq 100, Dow 30, Russell 2000, U.S. Dollar Index, Bitcoin Index
- Futures
- Bonds
US 10Y, Euro Bund, Germany 10Y, Japan 10Y Yield, UK 10Y, India 10Y
- Cryptocurrencies
- Scripts
- Editors' picks
- Oscillators
- Centered oscillators
- Volatility
- Trend analysis
- Volume
- Moving average
- Exponential Moving Average (EMA)
- Weighted Moving Average (WMA)
- Simple Moving Average (SMA)
- Hull Moving Average (HMA)
- Kaufman's Adaptive Moving Average (KAMA)
- Smoothed Moving Average (SMMA)
- Variable Index Dynamic Average (VIDYA)
- Volume-weighted Moving Average (VWMA)
- Fractal Adaptive Moving Average (FRAMA)
- Double Exponential Moving Average (DEMA)
- Breadth indicators
- Bill Williams indicators
- Screeners
- Streams
- Brokers
- Chart
- More
VALEO PHARMA INC
VPH
CSE
VALEO PHARMA INC
VPH CSE
VPH
VALEO PHARMA INC CSE
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
Upcoming Earnings
EPS
Market Cap
Div Yield
P/E
This is an interesting company, as someone who is in healthcare I have personally administer some of the drugs in this company's pipelines such as Ondansetron and Benztropine. They have a new supplement product called HesperCo, an antioxidant that may have potential for some sales. From an EWT point of view I believe we are in a corrective wave 2 in the form of...
0
Valuation
Enterprise Value/EBITDA, TTM
—
Enterprise Value, FQ
—
Market Cap — Basic
—
Number of Employees
—
Number of Shareholders
—
Price/Earnings, TTM
—
Price/Revenue, TTM
—
Price/Book Ratio, FY
—
Price/Sales Ratio, FY
—
Balance Sheet
Current Ratio, FQ
—
Debt to Equity, FQ
—
Net Debt, FQ
—
Quick Ratio, FQ
—
Total Assets, FQ
—
Total Debt, FQ
—
Operating Metrics
Return on Assets, TTM
—
Return on Equity, TTM
—
Return on Invested Capital, TTM
—
Revenue per Employee, TTM
—
Price History
Average Volume (10 day)
—
Beta - 1 Year
—
Price - 52 Week High
—
Price - 52 Week Low
—
Dividends
Dividends Paid, FY
—
Dividends per Share, FY
—
Expected Annual Dividends
—
Dividends Yield
—
Margins
Net Margin, TTM
—
Gross Margin, TTM
—
Operating Margin, TTM
—
Pretax Margin, TTM
—
Income Statement
Basic EPS, Net Income
—
Earnings per Share, Basic, TTM
—
EBITDA, TTM
—
Gross Profit, FY
—
Last Annual EPS
—
Last Annual Revenue, FY
—
Net Income, FY
—
Total Revenue, FY
—
Free Cash Flow, TTM
—
Sector: Health Technology
Industry: Pharmaceuticals: Major
Valeo Pharma, Inc. engages in the acquisitions, in-licensing or similar arrangements of patent protected, pharmaceutical products in specific therapeutic areas for the Canadian market. It focuses on injectable generic products. Its products include Onstryv, Synacthen,M-Eslon, Utrogestan, Ondansetron, and other hospital products. The company was founded by Steven Saviuk on March 27, 2003 and is headquartered in Kirkland, Canada.